MeiraGTx (MGTX) vs Odyssey Therapeutics (ODTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Odyssey Therapeutics is the larger company by market cap ($815.2 million vs $779.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MGTX | ODTX |
|---|---|---|
| Share price | $7.98 | $16.96 |
| Market cap | $779.89M | $815.23M |
| 1-day change | -1.97% | -7.52% |
| YTD return | +0.38% | — |
| 1-year return | +6.97% | — |
| 5-year return | -55.54% | — |
| P/E ratio (TTM) | 9.17 | — |
| EPS (TTM) | $0.87 | $-6.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $81.39M | — |
| Revenue growth (YoY) | +144.57% | — |
| Net income (latest FY) | $-114.20M | — |
| Operating margin | -130.20% | — |
| Net margin | -140.31% | — |
| 52-week high | $15.35 | $29.05 |
| 52-week low | $6.62 | $15.10 |
| Distance from 52-week high | -48.01% | -41.62% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +247.74% | +104.42% |
| Average volume | 837.25K | 329.31K |
| Shares outstanding | 97.73M | 48.07M |
| Employees | 386 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About MeiraGTx
MGTX stock →MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 386 employees
About Odyssey Therapeutics
ODTX stock →Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptorassociated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 100 employees
MGTX vs ODTX FAQ
Which is bigger, MeiraGTx or Odyssey Therapeutics?
Odyssey Therapeutics (ODTX) is larger, with a market capitalization of $815.23M compared with $779.89M for MeiraGTx (MGTX).
Are MeiraGTx and Odyssey Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.